Other studies in this section were designed against non-T cell malignancies, of which three utilized SLAMF7 (CSI) plus TRAC KO anti-SLAMF7 CAR T cells against multiple myeloma (MM) [36, 44, 63]. Here, SLAMF7 is linked to plasma cell myeloma.